Figure 1.

The advantages of ncRNAs against metastatic breast cancer (MBC) and the general structures for the non-viral delivery vehicles. (A) The advantages comparison between small molecular entities and ncRNAs. (B) The nanostructure difference between in vitro and in vivo applied nanoparticles. Aiming to prevent the degradation by RNase in vivo, ncRNAs must be loaded into the core of nanoparticles. Loading into the core of the nanoparticle will allow the ncRNA to be successfully applied in clinical settings.